Zalutumumab (powder)

Cat. No.: HY-P99155A: Data Sheet
FAQs
Technical Support

Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC₅₀s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer.

For research use only. We do not sell to patients.

Zalutumumab (powder) Chemical Structure

CAS No. : 667901-13-5

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Zalutumumab (powder):

Zalutumumab

Other Forms of Zalutumumab (powder):

Zalutumumab In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Biological Activity
Purity & Documentation
References
Customer Review

Description	Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC₅₀s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer^[1]^[2]^[3].
Molecular Weight	146.52 kDa
CAS No.	667901-13-5
SMILES	[Zalutumumab (powder)]
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (256 KB) Inhibitory Antibodies User Guide (602 KB)
References	[1]. Schick U, et al. Zalutumumab in head and neck cancer. Expert Opin Biol Ther. 2012 Jan;12(1):119-25. [Content Brief] [2]. Lammerts van Bueren JJ, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14. [Content Brief] [3]. Overdijk MB, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011 Sep 15;187(6):3383-90. [Content Brief]